MétaCan
Menu
Back to cohort

Insurance and Genetic Information

2017· other· en· W1593954915 on OpenAlexaff
Yvonne Bombard, Eugene Wong, Trudo Lemmens

Bibliographic record

VenueEncyclopedia of Life Sciences · 2017
Typeother
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicBRCA gene mutations in cancer
Canadian institutionsUniversity of TorontoSt. Michael's Hospital
Fundersnot available
KeywordsUnderwritingGenetic testingActuarial sciencePenetrancePopulationDiseaseMedical underwritingGenetic discriminationBusinessInsurabilityInsurance policyMedicineGeneticsBiologyInsurance lawGeneral insuranceEnvironmental healthPathologyGene

Abstract

fetched live from OpenAlex

Abstract Advances in genomic technology have expanded the number of tests for which individuals can obtain additional risk estimates about their susceptibilities to disease. Genomic information that predicts disease risk is relevant to insurers because the amount that policyholders pay for insurance coverage is determined by assessing their level of disease risk. Without access to genomic information, insurers are concerned that individuals may purchase more insurance at unadjusted premiums, leading to adverse selection. However, not all genomic information is useful from an insurance viewpoint, and the complexity of interpreting genetic variants, coupled with the possibility of incidental findings, raises ethical issues with using applicants' genomic testing results. Moreover, some people are reluctant to undergo genetic testing or participate in genomic research because of the fear that they may have difficulty in obtaining insurance after disclosing their genomic results to insurers. As genomic testing becomes more prevalent, there are concerns that sections of the population will be denied insurance because of their genetic profile. The question of what governments should do about this is one that has been debated in many countries. Key Concepts Insurers request genetic test results from applicants to enable them to make an accurate assessment of their health risks in the underwriting process. However, patients and the public fear that they may have difficulty in obtaining insurance after disclosing their genomic results to insurers. Not all genetic tests are useful for insurance underwriting; this will depend on the clinical validity and utility of the test, the nature and penetrance of the disease and the availability of treatment or management strategies. Use of genomic data for insurance underwriting also raises ethical concerns due to the complexity of interpreting genomic variants and the possibility of discovering incidental findings from genomic data. The public's fear of genetic discrimination by insurers appears to have consequences for public health and genetic research programme initiatives. Moratoria or legislation to prohibit the use of genetic test results by insurers has been adopted by many countries to prevent insurance discrimination. However, other ways to regulate the use of genetic tests in insurance include human rights or privacy‐based approaches.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.004
metaresearch head score (Gemma)0.017
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Other · Consensus signal: none
Teacher disagreement score0.027
Threshold uncertainty score0.089

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0040.017
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0020.002
Science and technology studies0.0020.008
Scholarly communication0.0050.004
Open science0.0010.003
Research integrity0.0050.004
Insufficient payload (model declined to judge)0.0270.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.009
GPT teacher head0.265
Teacher spread0.256 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreOther

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations7
Published2017
Admission routes1
Has abstractyes

Explore more

Same venueEncyclopedia of Life SciencesSame topicBRCA gene mutations in cancerFrench-language works237,207